secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2024-02-12T23:59:59+00:00
Accession:  0001764013-24-000025
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402
--------------------------------------------------------------------------------

- Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.
- IMVT-1402 Phase 1 showed 74% IgG reduction with no/minimal albumin or LDL changes vs placebo.
- Plans to start 4-5 potentially registrational IMVT-1402 programs by Mar 2025, 10 indications by Mar 2026.
- Batoclimab Phase 3 MG data expected 2H 2024; TED data 1H 2025; Phase 2b CIDP data 2Q/3Q 2024.
- R&D spend $48.3M in Q3, up from $42.3M, driven by IMVT-1402 development costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/imvt-20240212.htm
  HTML page:      https://secwatch.observer/filing/0001764013-24-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer